NYMX.F Stock Overview
A biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nymox Pharmaceutical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.14 |
| 52 Week High | US$1.40 |
| 52 Week Low | US$0.0001 |
| Beta | 8.71 |
| 1 Month Change | 133.33% |
| 3 Month Change | 27.27% |
| 1 Year Change | -74.07% |
| 3 Year Change | -87.16% |
| 5 Year Change | -94.21% |
| Change since IPO | -97.79% |
Recent News & Updates
Recent updates
Nymox gets FDA feedback on NDA resubmission for lead asset
Sep 13Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans?
Aug 17
NYMOX stock down 7.2% after receiving non-compliance letter from Nasdaq
Jul 14Nymox to file for Fexapotide approval by mid-September
May 06Nymox under pressure on $8M private placement
Apr 28What You Need To Know About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) Investor Composition
Mar 01Shareholder Returns
| NYMX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 75.0% | -3.6% | -2.4% |
| 1Y | -74.1% | -2.7% | 23.3% |
Return vs Industry: NYMX.F underperformed the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: NYMX.F underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| NYMX.F volatility | |
|---|---|
| NYMX.F Average Weekly Movement | 55.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NYMX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NYMX.F's weekly volatility has decreased from 2927% to 55% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Paul Averback | nymox.com |
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert for detecting smoking status; and TobacAlert for detecting second-hand smoke exposure.
Nymox Pharmaceutical Corporation Fundamentals Summary
| NYMX.F fundamental statistics | |
|---|---|
| Market cap | US$12.16m |
| Earnings (TTM) | -US$8.84m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs NYMX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYMX.F income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.84m |
| Earnings | -US$8.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.095 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -23.6% |
How did NYMX.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 08:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nymox Pharmaceutical Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Garner | Singular Research |
| Robert Young | Wm Smith & Co. |